Published in Am J Obstet Gynecol on April 02, 2011
Long-term outcomes following abdominal sacrocolpopexy for pelvic organ prolapse. JAMA (2013) 6.07
Lifetime risk of stress urinary incontinence or pelvic organ prolapse surgery. Obstet Gynecol (2014) 3.18
Surgical management of female SUI: is there a gold standard? Nat Rev Urol (2013) 1.84
Trends in the surgical management of stress urinary incontinence among female Medicare beneficiaries, 2002-2007. Urology (2013) 1.49
Interplay between bladder microbiota and urinary antimicrobial peptides: mechanisms for human urinary tract infection risk and symptom severity. PLoS One (2014) 1.44
Vaginal degeneration following implantation of synthetic mesh with increased stiffness. BJOG (2013) 1.19
Patients' understanding of pelvic floor disorders: what women want to know. Female Pelvic Med Reconstr Surg (2012) 1.11
Improving the accuracy of prolapse and incontinence procedure epidemiology by utilizing both inpatient and outpatient data. Int Urogynecol J (2013) 0.95
Clinical challenges in the management of vaginal prolapse. Int J Womens Health (2014) 0.94
Epidemiological trends and future care needs for pelvic floor disorders. Curr Opin Obstet Gynecol (2015) 0.89
Apical support at the time of hysterectomy for uterovaginal prolapse. Int Urogynecol J (2014) 0.89
Genetic epidemiology of pelvic organ prolapse: a systematic review. Am J Obstet Gynecol (2014) 0.88
Characterization of the host inflammatory response following implantation of prolapse mesh in rhesus macaque. Am J Obstet Gynecol (2015) 0.82
Native tissue repair for central compartment prolapse: a narrative review. Int Urogynecol J (2016) 0.82
Quality of information on pelvic organ prolapse on the Internet. Int Urogynecol J (2014) 0.82
The impact of prolapse mesh on vaginal smooth muscle structure and function. BJOG (2015) 0.82
The Single-Incision Sling to Treat Female Stress Urinary Incontinence: A Dynamic Computational Study of Outcomes and Risk Factors. J Biomech Eng (2015) 0.79
Perioperative and postoperative morbidity after sacrocolpopexy according to age in Korean women. Obstet Gynecol Sci (2015) 0.79
Physical activity and the pelvic floor. Am J Obstet Gynecol (2015) 0.78
Methods for a multicenter randomized trial for mixed urinary incontinence: rationale and patient-centeredness of the ESTEEM trial. Int Urogynecol J (2016) 0.78
Comparison of complications and prolapse recurrence between laparoscopic and vaginal uterosacral ligament suspension for the treatment of vaginal prolapse. Int Urogynecol J (2015) 0.78
Post-reduction stress urinary incontinence rates in posterior versus anterior pelvic organ prolapse: a secondary analysis. Int Urogynecol J (2013) 0.78
The pessary process: Spanish-speaking Latinas' experience. Int Urogynecol J (2012) 0.78
Risk factors for urgency incontinence in women undergoing stress urinary incontinence surgery. Adv Urol (2013) 0.77
Self-reported pelvic organ prolapse surgery, prevalence, and nonobstetric risk factors: findings from the Nord Trøndelag Health Study. Int Urogynecol J (2014) 0.76
Incidence and Risk Factors for Pelvic Pain After Mesh Implant Surgery for the Treatment of Pelvic Floor Disorders. J Minim Invasive Gynecol (2016) 0.75
Burch Retropubic Urethropexy Compared With Midurethral Sling With Concurrent Sacrocolpopexy: A Randomized Controlled Trial. Obstet Gynecol (2016) 0.75
The Epidemiology of Pelvic Floor Disorders and Childbirth: An Update. Obstet Gynecol Clin North Am (2016) 0.75
Trends in hysterectomy for genital prolapse: rural experience. Clin Med Insights Reprod Health (2013) 0.75
Introduction of laparoscopic sacral colpopexy to a fellowship training program. Int Urogynecol J (2013) 0.75
One-Year Outcomes After Minimally Invasive Sacrocolpopexy. Female Pelvic Med Reconstr Surg (2016) 0.75
Prevalence, Awareness, and Understanding of Pelvic Floor Disorders in Adolescent and Young Women. Female Pelvic Med Reconstr Surg (2016) 0.75
Analysis of voiding dysfunction after transobturator tape procedure for stress urinary incontinence. Korean J Urol (2015) 0.75
A study of transobturator tape in stress urinary incontinence. Urol Ann (2017) 0.75
Physical and cultural determinants of postpartum pelvic floor support and symptoms following vaginal delivery: a protocol for a mixed-methods prospective cohort study. BMJ Open (2017) 0.75
Intraoperative cervix location and apical support stiffness in women with and without pelvic organ prolapse. Am J Obstet Gynecol (2016) 0.75
Functional Outcomes for Incontinence and Prolapse Surgery. Curr Bladder Dysfunct Rep (2012) 0.75
MRI visible Fe3O4 polypropylene mesh: 3D reconstruction of spatial relation to bony pelvis and neurovascular structures. Int Urogynecol J (2017) 0.75
Transobturator versus single incision slings: 1-year results of a randomized controlled trial. Int Urogynecol J (2016) 0.75
A Meta-Analysis Detailing Overall Sexual Function and Orgasmic Function in Women Undergoing Midurethral Sling Surgery for Stress Incontinence. Sex Med (2017) 0.75
Robotic Sacrocolpopexy-Is It the Treatment of Choice for Advanced Apical Pelvic Organ Prolapse? Curr Urol Rep (2017) 0.75
Utilization of Apical Vaginal Support Procedures at Time of Inpatient Hysterectomy Performed for Benign Conditions: A National Estimate. Am J Obstet Gynecol (2017) 0.75
A validated translation of a survey for measuring incontinence knowledge in Chinese-speaking American immigrants. Int Urogynecol J (2016) 0.75
Perioperative complications following colpocleisis with and without concomitant vaginal hysterectomy. Int Urogynecol J (2017) 0.75
Pelvic organ prolapse: prevalence and risk factors in a Brazilian population. Int Urogynecol J (2016) 0.75
Primary care providers' attitudes, knowledge, and practice patterns regarding pelvic floor disorders. Int Urogynecol J (2016) 0.75
Outcomes following treatment for pelvic floor mesh complications. Int Urogynecol J (2013) 0.75
Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol (1997) 16.86
Prevalence of symptomatic pelvic floor disorders in US women. JAMA (2008) 7.81
Procedures for pelvic organ prolapse in the United States, 1979-1997. Am J Obstet Gynecol (2003) 5.15
Ambulatory surgery in the United States, 2006. Natl Health Stat Report (2009) 4.05
Cost of pelvic organ prolapse surgery in the United States. Obstet Gynecol (2001) 3.36
Annual direct cost of urinary incontinence. Obstet Gynecol (2001) 3.35
Forecasting the prevalence of pelvic floor disorders in U.S. Women: 2010 to 2050. Obstet Gynecol (2009) 3.08
Women seeking treatment for advanced pelvic organ prolapse have decreased body image and quality of life. Am J Obstet Gynecol (2006) 2.78
Trends in stress urinary incontinence inpatient procedures in the United States, 1979-2004. Am J Obstet Gynecol (2009) 2.33
The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int (2003) 1.93
A suite of web applications to streamline the interdisciplinary collaboration in secondary data analyses. BMC Med Res Methodol (2004) 1.74
Urologic diseases in America project: urinary incontinence in women-national trends in hospitalizations, office visits, treatment and economic impact. J Urol (2005) 1.72
Effect of patient age on increasing morbidity and mortality following urogynecologic surgery. Am J Obstet Gynecol (2006) 1.67
Ambulatory procedures for female pelvic floor disorders in the United States. Am J Obstet Gynecol (2010) 1.47
Trends in inpatient prolapse procedures in the United States, 1979-2006. Am J Obstet Gynecol (2010) 1.43
Predicting treatment choice for patients with pelvic organ prolapse. Obstet Gynecol (2003) 1.17
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med (2007) 7.31
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Forecasting the prevalence of pelvic floor disorders in U.S. Women: 2010 to 2050. Obstet Gynecol (2009) 3.08
Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol (2006) 3.08
Histological dating of timed endometrial biopsy tissue is not related to fertility status. Fertil Steril (2004) 3.03
Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med (2003) 2.72
The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis (2003) 2.72
Absence of secretory endometrium after false-positive home urine luteinizing hormone testing. Fertil Steril (2004) 2.59
Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol (2005) 2.50
Acute myocardial infarction in pregnancy: a United States population-based study. Circulation (2006) 2.49
Vaginal cuff dehiscence: risk factors and management. Am J Obstet Gynecol (2011) 2.42
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev (2013) 2.18
Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol (2013) 2.17
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Predictors of pregnancy in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2009) 1.90
Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA (2003) 1.89
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst (2006) 1.58
Nonsurgical management of heavy menstrual bleeding: a systematic review. Obstet Gynecol (2013) 1.57
The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. Fertil Steril (2006) 1.56
Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol (2013) 1.56
Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. Cancer (2010) 1.53
Occiput posterior fetal head position increases the risk of anal sphincter injury in vacuum-assisted deliveries. Am J Obstet Gynecol (2005) 1.53
FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol (2005) 1.52
Uterine artery embolization for treatment of leiomyomata: long-term outcomes from the FIBROID Registry. Obstet Gynecol (2008) 1.49
Ambulatory procedures for female pelvic floor disorders in the United States. Am J Obstet Gynecol (2010) 1.47
Nicotine replacement and behavioral therapy for smoking cessation in pregnancy. Am J Prev Med (2007) 1.44
Surgeon practice patterns for antibiotic prophylaxis in gynecologic surgery. Female Pelvic Med Reconstr Surg (2012) 1.44
Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer. Gynecol Oncol (2011) 1.44
HPV vaccines: now that they're here, how do we maximize their benefit? Contraception (2006) 1.41
Mesh erosion in abdominal sacral colpopexy with and without concomitant hysterectomy. Am J Obstet Gynecol (2006) 1.33
Venous thromboembolism prophylaxis in gynecologic surgery: a systematic review. Obstet Gynecol (2011) 1.31
Cost comparison among robotic, laparoscopic, and open hysterectomy for endometrial cancer. Obstet Gynecol (2010) 1.31
Fertility patients' views about frozen embryo disposition: results of a multi-institutional U.S. survey. Fertil Steril (2008) 1.30
Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. J Clin Endocrinol Metab (2010) 1.29
Effect of hysterectomy with ovarian preservation on ovarian function. Obstet Gynecol (2011) 1.28
Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making (2007) 1.28
The FIBROID Registry: symptom and quality-of-life status 1 year after therapy. Obstet Gynecol (2005) 1.22
Adherence to nicotine replacement therapy among pregnant smokers. Nicotine Tob Res (2009) 1.21
Ethylene vinyl alcohol copolymer erosions after use as a urethral bulking agent. Obstet Gynecol (2007) 1.14
Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab (2007) 1.14
Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis. Cost Eff Resour Alloc (2008) 1.14
Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol Oncol (2009) 1.12
The efficacy of posterior tibial nerve stimulation for the treatment of overactive bladder in women: a systematic review. Int Urogynecol J (2012) 1.11
Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. J Urol (2009) 1.10
Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests. Obstet Gynecol (2006) 1.09
Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? Gynecol Oncol (2008) 1.09
Management of adnexal mass. Evid Rep Technol Assess (Full Rep) (2006) 1.08
Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence. J Urol (2009) 1.06
Challenges and solutions for recruiting pregnant smokers into a nicotine replacement therapy trial. Nicotine Tob Res (2006) 1.01
Leiomyoma-related hospitalization and surgery: prevalence and predicted growth based on population trends. Am J Obstet Gynecol (2011) 1.00
Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples. J Low Genit Tract Dis (2010) 0.99
Projecting the need for gynecologic oncologists for the next 40 years. Obstet Gynecol (2010) 0.99
The impact of occiput posterior fetal head position on the risk of anal sphincter injury in forceps-assisted vaginal deliveries. Am J Obstet Gynecol (2005) 0.99
Should older women have antepartum testing to prevent unexplained stillbirth? Obstet Gynecol (2004) 0.97
Impact of the 2011 FDA transvaginal mesh safety update on AUGS members' use of synthetic mesh and biologic grafts in pelvic reconstructive surgery. Female Pelvic Med Reconstr Surg (2013) 0.96
Systematic review highlights difficulty interpreting diverse clinical outcomes in abnormal uterine bleeding trials. J Clin Epidemiol (2010) 0.96
Mesh sacrocolpopexy compared with native tissue vaginal repair: a systematic review and meta-analysis. Obstet Gynecol (2015) 0.96
Cost-effectiveness analysis of annual screening strategies for endometrial cancer. Am J Obstet Gynecol (2009) 0.96
Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis. Gynecol Oncol (2007) 0.94
Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol (2013) 0.94
Screening for cervical cancer: a modeling study for the US Preventive Services Task Force. J Low Genit Tract Dis (2013) 0.93
Effects of race and clinical factors on short-term outcomes of abdominal myomectomy. Obstet Gynecol (2003) 0.93
Utility scores and treatment preferences for clinical early-stage cervical cancer. Value Health (2011) 0.93
Pay-for-performance: a survey of specialty providers in urogynecology. J Reprod Med (2011) 0.93
Long-term outcomes after stress urinary incontinence surgery. Obstet Gynecol (2012) 0.93
The Fibroid Registry for outcomes data (FIBROID) for uterine embolization: short-term outcomes. Obstet Gynecol (2005) 0.93
Patient preferences for uterine preservation and hysterectomy in women with pelvic organ prolapse. Am J Obstet Gynecol (2013) 0.93
The effect of pelvic organ prolapse severity on improvement in overactive bladder symptoms after pelvic reconstructive surgery. Int Urogynecol J (2012) 0.92
High throughput, cell type-specific analysis of key proteins in human endometrial biopsies of women from fertile and infertile couples. Hum Reprod (2012) 0.91
Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening. Obstet Gynecol (2006) 0.91
Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women. J Adolesc Health (2012) 0.91
Smoking prevalence in early pregnancy: comparison of self-report and anonymous urine cotinine testing. J Matern Fetal Neonatal Med (2010) 0.91
HIV prevention in high-risk women in South Africa: condom use and the need for change. PLoS One (2012) 0.91
A systematic review comparing hysterectomy with less-invasive treatments for abnormal uterine bleeding. J Minim Invasive Gynecol (2011) 0.90
Uterosacral colpopexy at the time of vaginal hysterectomy: comparison of laparoscopic and vaginal approaches. J Reprod Med (2009) 0.89
Impact of a routine, opt-out HIV testing program on HIV testing and case detection in North Carolina sexually transmitted disease clinics. Sex Transm Dis (2014) 0.89
Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries. Obstet Gynecol (2002) 0.89
Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer. Int J Gynecol Cancer (2013) 0.88
Prioritization of patient-centered comparative effectiveness research for osteoarthritis. Ann Intern Med (2014) 0.88
Genomic tests for ovarian cancer detection and management. Evid Rep Technol Assess (Full Rep) (2006) 0.88
Effect of body mass index on the risk of anal incontinence and defecatory dysfunction in women. Am J Obstet Gynecol (2008) 0.88
Elective primary cesarean delivery: attitudes of urogynecology and maternal-fetal medicine specialists. Obstet Gynecol (2005) 0.88
Adverse birth outcomes among nulliparous vs. multiparous women. Public Health Rep (2011) 0.87
Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer. Cancer (2011) 0.87
Optimal timing of implantable cardioverter-defibrillator implantation after myocardial infarction: a decision analysis. J Cardiovasc Electrophysiol (2010) 0.86
Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer. Am J Obstet Gynecol (2010) 0.85
Prolapse symptoms in overweight and obese women before and after weight loss. Female Pelvic Med Reconstr Surg (2012) 0.85
Socioeconomic indicators and hysterectomy status in the United States, 2004. J Reprod Med (2009) 0.84
Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation. Value Health (2008) 0.84
A prospective study of weight gain after premenopausal hysterectomy. J Womens Health (Larchmt) (2009) 0.84
Pay for performance: what the urogynecologist should know. Int Urogynecol J Pelvic Floor Dysfunct (2008) 0.84